Hyaluronic acid derivatives containing groups able to release no

ABSTRACT

Disclosed are hyaluronic acid derivatives functionalised with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer.

The present invention relates to derivatives of hyaluronic acid (HA)functionalised with molecules containing S-nitrosothiol groups of thegeneral formula:

wherein HA indicates hyaluronic acid and G indicates a suitable spacer,in particular the N-acetylpenicillamine molecular fragment or cysteine(Cys).

The derivatives of the invention are able to release NO(NO-donors), andcan be used advantageously in dermatological and cosmetic applications,in particular to correct skin defects and for biorevitalisation oftissues after intradermal, subcutaneous or topical administration. Thederivatives according to the invention can also be used forcardiovascular applications and for the controlled release ofantitumoral, antiviral or antimicrobial drugs and/or agents.

PRIOR ART

Nitrous oxide (NO) acts in numerous parts of the body, being involved ina wide range of biological activities ranging from neurotransmission torelaxation of the smooth muscles, from vasodilation to the response toimmunogens, and makes a significant contribution to the maintenance ofhomeostasis, due to its free radical scavenging action. Of the variousareas in which NO operates, the skin, where NO acts at the level of thefibroblasts, keratinocytes and the complex series of events known aswound healing, is particularly important for the purposes of thisinvention (Cals-Grierson, Nitric Oxide, 2004, 10, 179-193). The use ofcompounds which directly or indirectly release nitrogen oxides wasrecently proposed for a variety of applications in thepharmaceutical/medical and cosmetic fields. See, for example, WO2006/097350, FR 2883170, WO 2006/095193, US 20040171589, EP 1442739, WO2003/049593, EP 1001677, WO 2006/100154 and U.S. Pat. No. 6,251,594.

S-Nitroso-N-acetylpenicillamine (SNAP) of formula

is a known commercial NO donor used mainly in biochemical andpharmacological studies (Zhang Y. et al., Free Radical Biology andMedicine 2005, volume 38, pp. 831-838 and Wang, P. G. et al., ChemicalReviews, 2002, 102, 1091-1134). For the scope of the present inventionboth D- (see formula) and L-enantiomer can be used indifferently.

Another molecule which is very suitable to derivatise HA, enabling thebiopolymer to release nitric oxide, is cysteine. Said amino acid can bebonded to HA through an amide bond in which HA participates through thecarboxyl group of glucuronic acid, and cysteine through the primaryamine function. The synthesis can be performed in an aqueous mediumusing amide formation promoters such as water-soluble carbodiimides(e.g. 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, EDC). The recentliterature (Kafedjiiski, K et. al., Int. J. Pharmaceut. 2007,doi:10.1016/J. pharm. Apr. 19, 2007), has demonstrated some interestingmucoadhesion properties of crosslinked derivatives prepared from HA-Cysconjugates; the authors have therefore proposed their use asmultipurpose excipients for the development of drug delivery systems.The present invention, however, uses the HA-Cys conjugate in the nativeform, i.e. not crosslinked by subsequent derivatisation to formconjugates of the general formula:

wherein GrPr indicates a generic carboxyl-protecting group, such as amethyl- or ethyl-ester.

DESCRIPTION OF THE INVENTION

It has now been found that hyaluronic acid derivatives functionalisedwith S-nitroso groups of formula

wherein HA indicates hyaluronic acid and G is a spacer between a carboxyor amino functional group of hyaluronic acid and respectively an aminoor carboxy functional group of a residue comprising a thiol group, areeffective donors of NO, which has a variety of uses in thepharmaceutical, cosmetic and medical fields.

Examples of G—S—N═O groups are N-acetylpenicillamine residues offormula:

or S-nitroso cysteine residues of formula:

(GrPr represents a protective group such as a C1-C4-alkyl group, inparticular methyl or ethyl).

The association between HA and a molecule able to release NO isadvantageous for all applications which require the activation ofcutaneous and/or dermal repair processes, such as lesions andsuperficial defects, aging and photoaging, and biorevitalisation of thedermal tissues. In these conditions, the known effects attributable toNO, such as:

-   -   increased collagen synthesis by the keratinocytes;    -   increased microcirculation;    -   facilitation of keratinocyte and fibroblast proliferation;    -   inducement of TGF-b1 (Transforming Growth Factor beta 1) and IL        synthesis, with consequent activation of the skin repair        processes;    -   stimulation of chemotactic release factors (such as        VEGF—Vascular Endothelial Growth Factor);

are surprisingly optimised by the association with hyaluronic acid or aderivative thereof.

The presence of hyaluronic acid or a derivative thereof:

-   -   allows synergic exploitation of the wound-healing, emollient,        humectant, repair and filling properties of hyaluronic acid        and/or its derivatives;    -   in view of the modulatability of the rheological characteristics        of HA as such and its derivatives, some very different        pharmaceutical forms can be obtained which are totally adaptable        to the site of application. Possible products are an injectable        gel for intradermal and/or subcutaneous administration to treat        wrinkles, scars and skin defects; hydrogels, creams, dressings        or films for topical application with a wound-healing,        biorevitalising and regenerating effect, gels with controlled        viscosity for drug delivery, to be administered by the systemic        or loco-regional (e.g. intra-articular) route, etc.    -   above all, maintains the product at the site of application for        longer, with consequent gradual release of NO. The conjugation        between HA and/or its derivatives and the source of NO is a        chemical bond, which ensures the stability of the product and        guarantees that the release of NO will be constant and        continuous.

Functionalisation with S-nitroso-N-acetyl-penicillamine groups mayinvolve amine groups deriving from deacetylation of theN-acetylglucosamine residues of hyaluronic acid or amine groupsintroduced by esterifying the carboxyl groups of the glucuronic acidunits with aminoalkyl residues.

In the first case, the derivatives according to the invention can beobtained from N-acetylpenicillamine or activated derivatives thereof,preferably from the corresponding cyclic anhydride or3-acetamido-4,4-dimethylthioethane-2-one (cAP), obtained fromN-acetyl-DL-penicillamine (AP) in the presence of pyridine and aceticanhydride according to the following reaction:

This reaction is promoted by the anhydrous medium using an excess ofacetic anhydride, preferably between 4 and 5 times the moles of AP. Thereaction takes place at a low temperature, between −20° and 5° C.,preferably 0° C., in a time interval of between 10 and 120 min,preferably 30 min. The compound cAP(3-acetamide-4,4-dimethylthioethane-2-one) is separated from thereaction mixture by adding a chlorinated organic solvent, preferablydichloromethane or chloroform.

The cAP thus obtained can therefore be reacted with partly deacetylatedhyaluronic acid or with aminoalkylesters of hyaluronic acid obtainablefrom alkaline salts, preferably sodium salts, of hyaluronic acid which,after transformation to a tetraalkylammonium salt, preferably tetrabutylammonium (TBA), through ion exchange and possibly subsequentfreeze-drying, are reacted with compounds of formula X-A-NH₂ wherein Xis a halogen atom, preferably bromine, and A is an aliphatic orarylaliphatic spacer residue having 2 to 16 carbon atoms, preferably a—(CH₂)_(n)— group, wherein n is an integer between 2 and 16, andpreferably between 2 and 7.

Specific examples of compounds of formula X—(CH₂)_(n)—NH₂ are2-bromo-1-ethylamine, 3-bromo-1-propylamine, and 7-bromo-1-heptylamine.These diamines are used in the form of salts, such as halohydrates.

Finally, the derivatives of the invention are obtained by subsequenttreatment with an alkyl nitrite.

The processes described above are illustrated in the following Schemes:

More particularly, to prepare aminoalkylesters, the HA-TBA salt issolubilised in an aprotic solvent such as N-methyl-pyrrolidone (NMP),N,N-dimethylformamide (DMF) or DMSO, in concentrations ranging between 3and 25 mg/ml, depending on the molecular weight of the HA.Halo-alkylamine is added to the reaction mixture in an almoststoichiometric amount, in agreement with the substitution degreerequired.

The reaction proceeds at a temperature of 25 to 40° C. for a time from24 to 96 hrs. Finally, the ester is separated from the reaction mixtureby alcoholic precipitation, preferably with ethanol, after ion exchangebetween the tetraalkylammonium salt and sodium.

After drying, the product is dissolved in DMF together with cAP in a 1:1stoichiometric ratio to the —NH₂ groups of the ester conjugate of HA,and the reaction proceeds for at least 30 min, after which the solventis removed. The product is taken up again in DMF, and an excess of alkylnitrite, preferably isopentyl nitrite, is added. The reaction proceedsat a low temperature, preferably −20° C.

The product is recovered by alcohol precipitation, preferably with 95°ethanol, and washed with absolute ethanol. The ester conjugate HA-SNAPis obtained in this way.

For the preparation of derivatives from partly de-N-acetylated HA, HA issolubilised in hydrazine or hydrazine hydrate with a purity of not lessthan 95%, at a concentration of between 1 and 50 mg/ml, and preferablybetween 5 and 25 mg/ml. An amount of hydrazine sulphate between 0.1 and3% w/v, preferably 1%, is added to the resulting solution.

The reaction is carried out at a temperature interval between 40 and 90°C., preferably 60° C., under constant stirring. The reaction timedepends on the percentage of de-N-acetylation to be obtained, but isbetween a few hrs and 50 hrs. The reaction is then arrested byprecipitation with a polar solvent, preferably ethanol. The precipitateis partly dried under vacuum, and treated with iodic acid having a molarconcentration of between 0.1 and 1 M, preferably 0.5 M, and then with57% (w/v) hydroiodic acid. The pH of the solution is maintained between5 and 7 by adding a 10% (w/v) solution of sodium acetate.

The aqueous phase containing the modified polysaccharide is subjected torepeated extraction with ethyl ether, until complete decolouring of theaqueous phase (initially dark yellow-brown). Finally, it is precipitatedwith a polar solvent, preferably ethanol. The product, recovered as awhite precipitate, is dried under vacuum for at least 48-72 hrs at 30°C.

Derivatisation of HA with S-nitroso cysteine residues comprises 2synthesis steps: reaction between HA and cysteine (Cys) and subsequenttransformation to the S-nitroso derivative.

The reaction between the biopolymer and the amino acid is convenientlycarried out starting from cysteine or derivatives, such as its carboxylesters (wherein Cys participates in the ester bond as acid) orthioesters (wherein Cys participates in the thioester bond as thiol).Cys or its derivatives are reacted with hyaluronic acid or its alkalinesalts, preferably the sodium salt, in an aqueous medium. Alternatively,the reaction can be conducted in an aprotic polar solvent such asN-methyl-pyrrolidone (NMP), N,N-dimethylformamide (DMF) or dimethylsulphoxide (DMSO) using an HA tetraalkylammonium salt. These salts areobtainable from alkaline salts, preferably sodium salts, of HA throughion exchange and possibly freeze-drying.

The formation of the amide bond between HA and Cys is promoted by addingto the reaction mixture an activating agent such as a carbodiimide, orcarbonyldiimidazole, or more generally using any activating agentclassically employed in peptide synthesis. If the reaction is conductedin water, Cys and HA or its alkaline salts are reacted through1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) in the presence ofN-hydroxysuccinimide (NHS). In the absence of NHS the reaction wouldbegin through the formation of O-acylisourea, an unstable intermediatewith a tendency to rearrange to give N-acylurea, a compound which is nolonger reactive towards amines. The addition of NHS allows the formationof an intermediate in the form of a non-rearrangeable activated ester,making coupling the primary amine to HA possible (J Biomed Mater Res.1999 November; 47(2):152-169 PMID:10449626). The reaction proceeds at apH of less than 8, and is promoted by a slightly acid pH. Thepreparation is carried out at a temperature between 0 and 45° C. andcompleted in less than 24 hrs, after which the conjugate is isolated byprecipitation with a solvent consisting of a water-alcohol mixture,alcohol-acetone or alcohol. The derivative can be purified by repeatedwashing with a water-alcohol mixture directly on the solid, or bydialysis.

The processes described above are illustrated in the following schemes:

In particular, the HA-Cys conjugate (Scheme 5) is synthesised bysolubilising HA (or its alkaline salts) in water to a concentration ofbetween 1 and 50 mg/ml, preferably between 3 and 25 mg/ml; an amount ofHCl/NaOH at the concentration of between 0.1 and 1M is added to thesolution thus obtained to adjust the pH to the interval 5.0-6.0, andpreferably around 5.5. At this point EDC, NHS, and Cys preferably in theform of ethyl ester are added. The protected amino acid is added in astoichiometric amount in relation to the substitution degree to beobtained, whereas EDC and NHS are added in slight stoichiometric excesscompared with the cysteine. Before the reaction mixture is incubated,the pH is further corrected to a value between 5 and 7, and preferablyaround 6. Synthesis is carried out at a temperature of between 0 and 45°C., for between 4 and 24 hrs, after which an amount of precipitantcorresponding to between 3 and 10 times the volume of the reactionmixture is added to said mixture. The precipitating solvent consists ofmixtures of polar solvents such as alcohols or acetone. The product isisolated by filtration or decanting, then washed until elimination ofthe ion content in solution, as verified by the specific conductivity ofthe washing water, which should reach a value of less than 30 μS/cm. Thelast wash is performed with absolute ethanol.

Alternatively, purification can be performed by dialysis against a NaClsolution with a concentration of between 0.5 and 5% w/v, preferably 1%,or against demineralised water. The product is then isolated as a solidby freeze-drying.

If the reaction is conducted in aprotic polar solvent (scheme 6) insteadof water, carbodiimides such as N,N′-di-cyclohexylcarbodiimide,N,N′-di-isopropylcarbodiimide, N,N′-di-toluoylcarbodiimide, orcarbonyldiimidazole in the presence of methanesulfonic acid can be usedto promote acylation of the primary amine group of the cysteine.

In this case the starting hyaluronic acid in the form of a tetraalkylammonium salt, preferably tetrabutyl ammonium, is dissolved in theaprotic solvent (NMP, DMF or DMSO) in concentrations ranging between 1and 25 mg/ml, depending on the molecular weight of the HA. Cys,preferably in the form of ethyl ester, is added to the reaction mixturein a stoichiometric amount or in slight excess compared with thesubstitution degree desired, together with the corresponding activatingagent. The reaction proceeds at a temperature of between 0 and 45° C.,for less than 24 hrs. At this stage the product is in the form of apartial ester of hyaluronic acid, the remaining carboxyl groups beingaccompanied by tetrabutylammonium counter-ions. An exchange is made withsodium ions by adding a volume of a saturated solution of sodiumchloride or sodium bromide amounting to 5-10% of the volume of thereaction mixture, and leaving it under stirring for not less than 30minutes. The product is precipitated by adding 3 to 10 volumes ofmixtures of polar solvents such as alcohols or acetone, after which itis isolated by filtration or decanting, and then washed until the ioncontent in solution has been eliminated, as verified by the specificconductivity of the washing water, which must not exceed 30 μS/cm. Thelast wash is performed with absolute ethanol.

The HA-Cys derivative should be protected against air and humidity,preferably by storing it in a refrigerator at a temperature of between 2and 8° C.

The HA-Cys conjugate is then transformed into the S-nitroso derivative(Scheme 7). Said transformation can be effected by reaction with HNO₂,generated in situ by acidification of NaNO₂ with HCl or by reaction withan alkyl nitrite.

The synthesis is conducted at a temperature of between −5° C. and 25° C.in aqueous solvent, or in water/ether solvent mixtures such astetrahydrofuran (THF) or dioxane, and is completed in 24-48 hrs.

The product is isolated by precipitation by adding ethanol/watermixtures (preferably ethanol/water 96/4) or methanol-acetone, preferablyin the ratio of 2/1 or 1/1.

The HA used in this invention may derive from any source; for example,it may be produced by extraction from rooster combs (EP 138572 B1),fermentation (EP 716688 B1) or biotechnology, and have a molecularweight of between 400 and 3×10⁶ Da, preferably between 1×10⁵ Da and1×10⁶ Da, and even more preferably between 200,000 and 750,000 Da.

The derivatisation reaction according to the invention can be appliedboth to the polysaccharide as is, and to the polysaccharide previouslymodified. Molecular networks will therefore be obtained from hyaluronicacid which are variously modified in accordance with known methods, inparticular:

HA salified with organic and/or inorganic bases (EP 138572 B1);

HYAFF®: HA esters with alcohols of the aliphatic, arylaliphatic,cycloaliphatic, aromatic, cyclic and heterocyclic series, with anesterification percentage which can vary, depending on the type andlength of the alcohol used, preferably between 50 and 100%, while theremaining percentage of non-esterified HA can be salified with organicand/or inorganic bases (EP 216453 B1);

HYADD®: HA amides with amines of the aliphatic, arylaliphatic,cycloaliphatic, aromatic, cyclic and heterocyclic series, with anamidation percentage ranging between 0.1 and 50%, while the remainingpercentage of non-amidated HA can be salified with organic and/orinorganic bases (EP 1095064 B1);

O-sulphated derivatives of HA up to the 4th degree of sulphation (EP702699 B1);

ACP®: internal esters of HA with an esterification percentage notexceeding 20%, preferably between 0.05 and 10% of esterification, whilethe remaining percentage of non-esterified HA can be salified withorganic and/or inorganic bases (EP 341745 B1);

HA deacetylates: derive from deacetylation of the N-acetylglucosamineresidues present in HA, with a deacetylation percentage preferablybetween 0.1 and 30%, while all the carboxyl groups of HA can be salifiedwith organic and/or inorganic bases (EP 1313772 B1);

HYOXX™: percarboxylated derivatives of HA obtained by oxidation of theprimary hydroxyl of the N-acetyl-glucosamine fraction with a degree ofpercarboxylation of between 0.1 and 100%, and preferably between 25 and75%. All the carboxyl groups of HA can be salified with organic and/orinorganic bases (EP 1339753 A).

As already stated, the derivatives according to the invention, obtainedafter derivatisation of hyaluronic acid, retain the biologicalproperties of the starting polysaccharide, but have different mechanicaland rheological properties. It is therefore possible to select the mostsuitable derivative, depending on the type of application chosen for theend product.

The invention is described in greater detail in the examples below.

Example 1 Preparation of HA-Propylamine Ester Derivative (200 kDa)

5.00 g of extractive hyaluronic acid sodium salt hyalastine fraction (Mwapprox. 200 kDa) is dissolved in 250 ml of water, and the resultingsolution is percolated through a glass column pre-packed with 100 cm³ ofDowex resin in the form of tetrabutylammonium. The eluted solution of HATBA salt is collected and freeze-dried. 7.50 g of product is obtained,and dissolved in 400 ml of N-methyl-pyrrolidone (NMP).

After complete solubilisation of the HA salt, 0.53 g of3-bromo-1-propanamine hydrobromide are added and the mixture is left toreact at 35° C. for 48 h under gentle stirring. Finally, the reaction isarrested by adding 0.1 volumes of a NaCl saturated aqueous solution; 30min later, 3 volumes of absolute ethanol are added to the solution toseparate the HA ester from the reaction mixture. The precipitate iswashed again with ethanol, and finally dried under high vacuum at 40° C.4.49 g of HA-COO(CH₂)₃.NH₂ ester derivative is obtained. Thesubstitution degree is 25% moles/moles.

Example 2 Preparation of HA-Ethylamine Ester Derivative (750 kDa)

3.00 g of extractive hyaluronic acid sodium salt, hyalectin fraction (Mwapprox. 750 kDa), is dissolved in 600 ml of water, and the resultingsolution is percolated through a glass column pre-packed with 100 cm³ ofDowex resin in the form of tetrabutylammonium. The eluted solution of HATBA salt is collected and freeze-dried. 4.20 g of product is obtained,and dissolved in 400 ml of N-methyl-pyrrolidone (NMP).

After complete solubilisation of the HA salt, 0.90 g of2-bromoethylamine hydrobromide are added, and leave the mixture to reactat 35° C. for 48 h under gentle stirring. Finally, the reaction isarrested by adding 0.1 volumes of a NaCl saturated aqueous solution; 30min later, 2.5 volumes of absolute ethanol are added to the solution toseparate the HA ester from the reaction mixture. The precipitate iswashed again in ethanol, and finally dried under high vacuum at 40° C.2.25 g of HA-COO(CH₂)₂.NH₂ ester derivative is obtained. Thesubstitution degree is 50% moles/moles.

Example 3 Preparation of HA-Heptylamine Ester Derivative (15 kDa)

6.00 g of fermentative hyaluronic acid sodium salt, LMW (Low MolecularWeight) fraction (15 kDa), is dissolved in 300 ml of water, and theresulting solution is percolated through a glass column pre-packed with120 cm³ of Dowex resin in the form of tetrabutylammonium. The elutedsolution of HA TBA salt is collected and freeze-dried. 8.43 g of theproduct is obtained, and dissolved in 420 ml of N,N dimethylformamide(DMF).

After complete solubilisation of the LMW HA salt, 0.66 g of7-bromoheptylamine hydrobromide are added and left to react at 35° C.for 72 h under gentle stirring. Finally, the reaction is arrested byadding 0.1 volumes of a NaCl saturated aqueous solution; 30 min later,2.5 volumes of absolute ethanol are added to the solution to separatethe HA ester from the reaction mixture. The precipitate is washed againin ethanol, and finally dried under high vacuum at 40° C. 4.70 g ofHA-COO(CH₂)₇.NH₂ ester derivative is obtained. The substitution degreeis 10% moles/moles.

Example 4 Preparation of HA-Propyl-SNAPp25 Ester Derivative

4.00 g of N-acetyl-DL-penicillamine compound (AP) is dissolved in 8 mlof pyridine in the presence of 8 ml of acetic anhydride. The reactionproceeds for 30 min at 0° C. and overnight at room temperature, alwaysunder gentle stirring. The reaction is arrested by evaporation, and theresidue is taken up with at least 100 ml of dichloromethane. Then theorganic solution is extracted at least 3 times with 50 ml of an aqueousacid solution (approx. 1 M HCl), filtered, and finally evaporated todryness. The residue is washed with 50 ml of ethyl ether. 1.80 g ofcyclic cAP derivative (3-acetamide-4,4-dimethylthioethane-2-one) isobtained.

4.00 g of the derivative obtained as described in Example 1 and 1.70 gof cAP are dissolved in 200 ml of DMF, and stirring is maintained for 30min at room temperature. After removal of the solvent, the residue istaken up with the minimum volume of DMF and treated with isopentylnitrite at −20° C. for 2 hrs. Temperature is increased to between 15 and25° C., the mixture is precipitated in 3 volumes of ethanol, and theproduct is washed with absolute ethanol. After drying under high vacuum,4.11 g of HA-propyl-SNAPp25 ester derivative is obtained.

Example 5 Preparation of HA-Ethyl-SNAPp50 Ester Derivative

3.00 g of N-acetyl-DL-penicillamine compound (AP) is dissolved in 6 mlof pyridine in the presence of 6 ml of acetic anhydride. The reactionproceeds for 30 min at 0° C. and overnight at room temperature, alwaysunder gentle stirring. The reaction is arrested by evaporation, and theresidue is taken up with at least 80 ml of dichloromethane. Then theorganic solution is extracted at least 3 times with 50 ml of an aqueousacid solution (approx. 1 M HCl), filtered, and finally evaporated todryness. The residue is washed with 50 ml of ethyl ether. 1.21 g ofcyclic cAP derivative (3-acetamide-4,4-dimethylthioethane-2-one) isobtained.

2.00 g of the derivative obtained as described in Example 2 and 1.10 gof cAP are dissolved in 100 ml of DMF, and stirring is maintained for 30min at room temperature. After removal of the solvent, the residue istaken up with the minimum volume of DMF and treated with isopentylnitrite at −20° C. for 2 h. Temperature is increased to between 15 and25° C., the mixture is precipitated in 3 volumes of ethanol, and theproduct is washed with absolute ethanol. After drying under high vacuum.2.27 g of HA-ethyl-SNAPp50 ester derivative is obtained.

Example 6 Preparation of HA-Heptyl-SNAPp10 Ester Derivative

2.00 g of N-acetyl-DL-penicillamine compound (AP) is dissolved in 4 mlof pyridine in the presence of 4 ml of acetic anhydride. The reactionproceeds for 30 min at 0° C. and overnight at room temperature, alwaysunder gentle stirring. The reaction is arrested by evaporation, and theresidue is taken up with at least 60 ml of dichloromethane. Then theorganic solution is extracted at least 3 times with 50 ml of an aqueousacid solution (approx. 1 M HCl), filtered, and finally evaporated todryness. The residue is washed with 50 ml of ethyl ether. 0.90 g ofcyclic cAP derivative (3-acetamide-4,4-dimethylthioethane-2-one) isobtained.

4.00 g of the derivative obtained as described in Example 3 and 0.70 gof cAP are dissolved in 200 ml of DMF, and stirring is maintained for 30min at room temperature. After removal of the solvent, the residue istaken up with the minimum volume of DMF and treated with isopentylnitrite at −20° C. for 2 h. Temperature is increased to between 15 and25° C., the mixture is precipitated in 3 volumes of ethanol, and theproduct is washed with absolute ethanol. After drying under high vacuum.3.25 g of HA-heptyl-SNAPp10 ester derivative is obtained.

Example 7 Preparation of 23% HA-De-N Acetylate Derivative

1.00 g of fermentative HA with a molecular weight of 210 kDa isdissolved in 100 ml of hydrazine monohydrate together with 1.00 g ofhydrazine sulphate. The solution is maintained under stirring for 48 hat 60° C., then the reaction is arrested by adding 150 ml of ethanol.The precipitate in gel form is washed and dried dry at room temperatureovernight.

Then the intermediate is redissolved in 100 ml of distilled water and 20ml of 10% w/v sodium acetate solution, and 30 ml of a 0.5 M iodic acidsolution is added. After 30 minutes, 5 ml of 57% hydriodic acid isadded. During this last operation, the temperature is maintained at 0°C. with an ice bath.

The aqueous solution, which has a deep brown colour, is treated byliquid-liquid extraction at least five times with 50 ml of ethyl ether.Finally, the pH of the decoloured solution containing the modifiedpolysaccharide is adjusted to between 6.5 and 7 with 1 N NaOH, and theproduct is precipitated with 200 ml of ethanol. The white precipitate iswashed with ethanol and dried under vacuum for at least 48 hrs. 0.94 gof HA-De-acetylate is obtained, and the degree of deacetylation is 23%.

Example 8 Preparation of HA-N-SNAPp23 Derivative

2.00 g of N-acetyl-DL-penicillamine compound (AP) is dissolved in 4 mlof pyridine in the presence of 4 ml of acetic anhydride. The reactionproceeds for 30 min at 0° C. and overnight at room temperature, alwaysunder gentle stirring. The reaction is arrested by evaporation, and theresidue is taken up with at least 60 ml of dichloromethane. Then theorganic solution is extracted at least 3 times with 50 ml of an aqueousacid solution (approx. 1 M HCl), filtered, and finally evaporated todryness. The residue is washed with 50 ml of ethyl ether. 0.92 g ofcyclic cAP derivative (3-acetamide-4,4-dimethylethane-2-one) isobtained.

0.80 g of the derivative obtained as described in Example 7 and 0.70 gof cAP are dissolved in 100 ml of DMF, and stirring is maintained for 30min at room temperature. After removal of the solvent, the residue istaken up with the minimum volume of DMF and treated with isopentylnitrite at −20° C. for 2 h. Temperature is increased to between 15 and25° C., the mixture is precipitated in 3 volumes of ethanol, and washedwith absolute ethanol. After drying under high vacuum. 1.04 g ofHA-N-SNAPp23 derivative is obtained.

Example 9 Preparation of HA-Cys p25 Derivative (200 kDa)

5.00 g of fermentative hyaluronic acid sodium salt, hyalastine fraction(Mw 200 kDa), is dissolved in 300 ml of water. The solution is addedwith an amount of 1M HCl/NaOH sufficient to adjust the pH to 5.5. 0.60 gof cysteine-ethyl ester hydrochloride, 0.61 g of EDC and 0.36 g of NHSare added; when they have dissolved, the pH of the reaction mixture isadjusted to around 6. The mixture is left to react at room temperature(24° C.) for 24 hrs, periodically checking the pH, and adjusting ifnecessary with 0.1 M HCl/NaOH to maintain the value at around 6. At theend of the reaction, the pH is adjusted to around 7, and the product isprecipitated with 4 volumes of 96% ethanol.

The product is recovered by filtration and washed with 8/2, then 9/1mixtures of ethanol/water until elimination of the content of ions insolution, as verified by the specific conductivity of the washing water,which should reach a value of less than 30 μS/cm. After a last wash withabsolute ethanol, the product is dried under vacuum at 40° C. toconstant weight. The product appears as a white hygroscopic solid,weighing 4.44 g. It should be stored under nitrogen atmosphere at aTemperature below 6° C. The substitution degree is 24% moles/moles.

Example 10 Preparation of HA-Cys p50 Derivative (750 kDa)

3.00 g of extractive hyaluronic acid sodium salt, hyalectin fraction (Mwapprox. 750 kDa), is dissolved in 600 ml of water, and the resultingsolution is percolated through a glass column pre-packed with 100 cm³ ofDowex resin in the form of tetrabutylammonium. The eluted solution of HATBA salt is collected and freeze-dried. 4.12 g of product is obtained,and dissolved in 450 ml of DMSO. 0.60 g of cysteine-ethyl esterhydrochloride and 0.70 g of N,N′-di-cyclohexylcarbodiimide (DCC) areadded. The mixture is left to react at room temperature (24° C.) for 24hrs, and slowly added with 50 ml of saturated NaCl solution (330 g/l).The product is precipitated by slowly adding 2 l of 96° ethanol. Theproduct is washed with an 8/2 ethanol/water mixture to a specificconductivity of less than 30 μS/cm, then washed with absolute ethanoland dried under vacuum at 40° C. to constant weight. The product appearsas a white hygroscopic solid, weighing 3.09 g. It should be stored undernitrogen atmosphere at a Temperature below 6° C. The substitution degreeis 47% by moles.

Example 11 Preparation of LMW HA-Cys p50 Derivative

5.00 g of fermentative hyaluronic acid sodium salt with a low molecularweight (Mw 15 kDa) is dissolved in 250 ml of water. The solution isadded with an amount of 1M HCl/NaOH sufficient to adjust the pH to 5.5.Add 1.20 g of cysteine-ethyl ester hydrochloride, 1.22 g of EDC and 0.72g of NHS; when they have dissolved, the pH of the reaction mixture isadjusted to around 6. The mixture is left to react at room temperature(24° C.) for 24 hrs, taking care to check the pH periodically, andcorrect if necessary with 0.1 M HCl/NaOH to maintain the value at around6. At the end of the reaction, the pH is adjusted to around 7, and theproduct is precipitated with 3 volumes of 1/1 methanol/acetone mixture.The product is recovered by filtration, then washed with 96% ethanoluntil elimination of the content of ions in solution, as verified by thespecific conductivity of the washing water, which should reach a valueof less than 30 μS/cm. After a last wash with absolute ethanol, theproduct is dried under vacuum at 40° C. to constant weight. The productappears as a white hygroscopic solid, weighing 4.32 g. It should bestored under nitrogen atmosphere at a Temperature below 6° C. Thesubstitution degree is 52% moles/moles.

Example 12 Preparation of LMW HA-Cys-S-Nitric Oxide P50 Derivative

4.00 g of the product obtained as described in example 11 are dissolvedin 250 ml of water. 0.50 g of sodium nitrite NaNO₂ is added, thereaction mixture is cooled to the temperature of 5° C. and slowly addedwith 7.2 ml of 1N HCl. After 2 hrs, the mixture is left to heat (warm)to room temperature. The product is recovered by precipitation with 96%ethanol, washed with the same solvent, and dried at 40° C. under vacuum.3.87 g of the product is obtained, which should be stored under nitrogenatmosphere at a Temperature below 6° C.

Example 13 Preparation of HA-Cys-S-Nitric Oxide p50 Derivate (750 kDa)

3.00 g of the product obtained as described in example 10 is dissolvedin 350 ml of water. 0.30 g of sodium nitrite NaNO₂ is added, thereaction mixture is cooled to the temperature of 5° C. and slowly addedwith 4.3 ml of 1N HCl. After 2 hrs, the mixture is left to warm to roomtemperature. The product is recovered by precipitation with 96% ethanol,washed with the same solvent, and dried at 40° C. under vacuum. 2.69 gof the product is obtained, which should be stored under nitrogenatmosphere at a Temperature below 6° C.

Example 14 Preparation of LMW HA-Cys-S-Nitric Oxide p50 Derivative viaAlkyl Nitrite

4.00 g of the product obtained as described in example 11 is dissolvedin the minimum amount of DMF. The mixture is treated with isopentylnitrite at −20° C. for 2 h. The product is recovered by precipitationwith 3 volumes of 96% ethanol, washed with the same solvent, and driedat 40° C. under vacuum. 3.61 g of the product is obtained, which shouldbe stored under nitrogen atmosphere at a Temperature below 6° C.

Example 15 Characterisation of the Compounds by FTIR

FIG. 1 shows the FTIR spectrum (Jasco FT/IR-4100 spectrophotometer) ofthe conjugate between HA and cysteine ethyl ester (broken line) and HAsodium salt (continuous line). In the region of the wave numbers around1700 cm⁻¹ (carbonyl bond stretching modes) a new band is evident at 1740cm⁻¹, which was not observed in the starting reagents. This indicatesthe formation of a covalent bond between the biopolymer and theprotected amino acid.

FIG. 2 compares the FTIR spectrum of the conjugate between HA andcysteine and HA sodium salt. Once again, the most significant differenceis the presence of a new band not found in the starting reagents,located at 1735 cm⁻¹, and attributable to the formation of the newcovalent species.

Example 16 Release Test

The nitric oxide (NO) release profile of the compounds of the inventionwas evaluated by spectrophotometry using the Griess test. The trend ofNO release by the HA-Cys conjugate in S-nitroso form, prepared asdescribed in example 13, is shown here by way of example. Briefly: 4 mgof the product is dissolved in 2.5 ml of Griess reagent in a UV-visiblespectrophotometric cuvette. The solution is rapidly homogenised, placedin a double-beam spectrophotometer (Perkin Elmer Lambda 2), and theabsorbance trend is measured at 540 nm over time against a blankconsisting of Griess solution. The results are shown in FIG. 3. Theabsorbance, i.e. the nitric oxide concentration, increases in thesolution with an asymptotic trend, the plateau of which has not yet beenreached 25 hrs after release. Assuming first-order kinetics, a decayconstant amounting to 70 min⁻¹ is obtained.

The gradual release of NO combined with the wound-healing, emollient,humectant, repair and filling properties of hyaluronic acid and/orderivatives thereof make the compounds of the invention particularlysuitable for use in dermatological, cosmetic and cardiovascularapplications and for the controlled release of drugs.

1. A hyaluronic acid derivative functionalised with S-nitrosothiolgroups of the general formula:

wherein HA indicates hyaluronic acid and G indicates a suitable spacer.2. The hyaluronic acid derivative according to in claim 1, whereinspacer G is an N-acetylpenicillamine residue of formula:


3. The hyaluronic acid derivative according to claim 1, wherein spacer Gis a cysteine residue of formula:

wherein GrPr represents a protective group.
 4. The hyaluronic acidderivative according to any one of claims 1 and 2, wherein thefunctionalisation with S-nitroso-N-acetylpenicillamine groups mayinvolve amine groups deriving from deacetylation of theN-acetylglucosamine residues of hyaluronic acid or amine groupsintroduced by esterifying the carboxyl groups of the glucuronic acidunits with aminoalkyl residues.
 5. The hyaluronic acid derivativeaccording to claim 1, wherein the functionalisation with cysteine,possibly protected as carboxyl ester, involves the carboxyl groupspresent in the glucuronic acid residues of hyaluronic acid.
 6. Thehyaluronic acid derivative according to claim 1, wherein thefunctionalisation with S-nitroso-N-acetylpenicillamine orS-nitroso-cysteine groups relates to amine groups deriving fromdeacetylation of the N-acetylglucosamine residues of hyaluronic acid. 7.The hyaluronic acid derivative according to claim 1, wherein thefunctionalisation with S-nitroso-N-acetylpenicillamine orS-nitroso-cysteine groups involves amine groups introduced byesterifying the carboxyl groups of the glucuronic acid units withresidues of formula X-A-NH2, wherein X is a halogen atom, preferablybromine, and A is an aliphatic or arylaliphatic spacer residue having 2to 16 carbon atoms, preferably a —(CH2)_(n)— group where n is an integerbetween 2 and 16, and preferably between 2 and
 7. 8. The hyaluronic acidderivative according to claim 1, wherein the hyaluronic acid is ofextractive, fermentative or biotechnological origin and has a molecularweight of between 400 and 3×10⁶ Da, in particular between 1×10⁵ Da and1×10⁶ Da, and even more particularly between 200,000 and 750,000 Da. 9.The hyaluronic acid derivative according to claim 1 for dermatologicaland cosmetic applications, in particular for the correction of skinlesions and defects, biorevitalisation of tissues, tissue healing afterintradermal, subcutaneous or topical administration, for cardiovascularapplications and controlled release of drugs, after systemic and/orlocoregional administration.
 10. A cosmestic or pharmaceuticalcomposition or medical device containing at least one hyaluronic acidderivative according to claim 1.